source
- Eli Lilly's $3.8 B acquisition of AtaiBeckley signals growing confidence in psychedelics for depressionPsychedelics are being touted as a potential solution for patients who still struggle to find lasting relief from existing FDA‑approved psychiatric medicines. The article notes that many individual…
- AbCellera's Phase 2 hot flash trial beats aggressive upside target, challenging Astellas and BayerAbCellera announced that its Phase 2 study of ABCL635, an antibody that blocks the NK3R receptor, met its primary endpoint in postmenopausal women with hot flashes. The trial enrolled 92 participan…Fierce Biotech · 1d agoPositive readoutPositive